SCHEMBL5029324

SCHEMBL5029324

Cc1ccc(F)c(NC(=O)c2ccc(C)c(Nc3nc(-c4ccncc4)cs3)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.57
ABL1 P00519 8/20 0.50
BCR P11274 8/20 0.50
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
ROCK1 Q13464 3/20 0.48
HDAC6 Q9UBN7 2/20 0.47
HDAC3 O15379 1/20 0.47
PDGFRB P09619 1/20 0.47
KDR P35968 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
MPL P40238 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025029 0.93 GAA (0.54) GAAABL1BCRMEN1KMT2A
SCHEMBL5023723 0.89 ABL1 (0.55) ABL1BCRMEN1KMT2AMPL
SCHEMBL5025258 0.87 ROCK1 (0.64) GAAABL1BCRMEN1KMT2A
SCHEMBL5027669 0.87 ABL1 (0.55) ABL1BCRMEN1KMT2AHDAC6
SCHEMBL5023693 0.86 MAPT (0.59) GAAABL1BCRMEN1KMT2A
SCHEMBL5025047 0.86 ABL1 (0.56) GAAABL1BCRROCK1HDAC6
SCHEMBL5027660 0.85 MAPT (0.62) GAAABL1BCRMEN1KMT2A
SCHEMBL5025230 0.85 ROCK1 (0.59) ABL1BCRMEN1KMT2AROCK1
SCHEMBL5023703 0.84 GAA (0.69) GAAABL1BCRMEN1KMT2A
SCHEMBL5023713 0.83 ROCK1 (0.49) GAAABL1BCRKMT2AROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US claimed
CN-1934107-A 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors AB SCIENCE (FR) 2007-03-21 CN claimed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
CN-1934107-A 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors AB SCIENCE (FR) 2007-03-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors KIT, MAP3K2, RET GAA 655/4885ABL1 22/4885BCR 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.